101 related articles for article (PubMed ID: 21902681)
1. KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts.
Miki H; Ozaki S; Nakamura S; Oda A; Amou H; Ikegame A; Watanabe K; Hiasa M; Cui Q; Harada T; Fujii S; Nakano A; Kagawa K; Takeuchi K; Yata K; Sakai A; Abe M; Matsumoto T
Br J Haematol; 2011 Nov; 155(3):328-39. PubMed ID: 21902681
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
3. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
4. Selective accumulation of the endoplasmic reticulum-Golgi intermediate compartment induced by the antitumor drug KRN5500.
Kamishohara M; Kenney S; Domergue R; Vistica DT; Sausville EA
Exp Cell Res; 2000 May; 256(2):468-79. PubMed ID: 10772819
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells.
Kamishohara M; Kawai H; Sakai T; Isoe T; Hasegawa K; Mochizuki J; Uchida T; Kataoka S; Yamaki H; Tsuruo T
Oncol Res; 1994; 6(8):383-90. PubMed ID: 7894087
[TBL] [Abstract][Full Text] [Related]
6. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
7. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
8. Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.
Ramasamy K; Khatun H; Macpherson L; Caley MP; Sturge J; Mufti GJ; Schey SA; Calle Y
Br J Haematol; 2012 Jun; 157(5):564-79. PubMed ID: 22428569
[TBL] [Abstract][Full Text] [Related]
9. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells.
Yata K; Yaccoby S
Leukemia; 2004 Nov; 18(11):1891-7. PubMed ID: 15385929
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
11. A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment.
Sekimoto E; Ozaki S; Ohshima T; Shibata H; Hashimoto T; Abe M; Kimura N; Hattori K; Kawai S; Kinoshita Y; Yamada-Okabe H; Tsuchiya M; Matsumoto T
Cancer Res; 2007 Feb; 67(3):1184-92. PubMed ID: 17283154
[TBL] [Abstract][Full Text] [Related]
12. Etodolac induces apoptosis and inhibits cell adhesion to bone marrow stromal cells in human myeloma cells.
Nakamura S; Kobayashi M; Shibata K; Sahara N; Shigeno K; Shinjo K; Naito K; Hayashi H; Ohnishi K
Leuk Res; 2006 Feb; 30(2):123-35. PubMed ID: 16046235
[TBL] [Abstract][Full Text] [Related]
13. Investigation of antitumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo.
Wu KD; Cho YS; Katz J; Ponomarev V; Chen-Kiang S; Danishefsky SJ; Moore MA
Proc Natl Acad Sci U S A; 2005 Jul; 102(30):10640-5. PubMed ID: 16030145
[TBL] [Abstract][Full Text] [Related]
14. Promising preclinical activity of 2-methoxyestradiol in multiple myeloma.
Dingli D; Timm M; Russell SJ; Witzig TE; Rajkumar SV
Clin Cancer Res; 2002 Dec; 8(12):3948-54. PubMed ID: 12473611
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of a spicamycin derivative, KRN5500, on the growth of hepatic metastasis of human colon cancer-producing tissue polypeptide antigen.
Kamishohara M; Kawai H; Sakai T; Uchida T; Tsuruo T; Otake N
Cancer Chemother Pharmacol; 1996; 38(6):495-8. PubMed ID: 8823489
[TBL] [Abstract][Full Text] [Related]
16. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
[TBL] [Abstract][Full Text] [Related]
17. Curcuma wenyujin extract induces apoptosis and inhibits proliferation of human cervical cancer cells in vitro and in vivo.
Lim CB; Ky N; Ng HM; Hamza MS; Zhao Y
Integr Cancer Ther; 2010 Mar; 9(1):36-49. PubMed ID: 20150221
[TBL] [Abstract][Full Text] [Related]
18. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
[TBL] [Abstract][Full Text] [Related]
19. Spicamycin and KRN5500 induce apoptosis in myeloid and lymphoid cell lines with down-regulation of bcl-2 expression and modulation of promyelocytic leukemia protein.
Zhang WJ; Ohnishi K; Yoshida H; Pan L; Maksumova L; Muratkhodjaev F; Luo JM; Shigeno K; Fujisawa S; Naito K; Nakamura S; Shinjo K; Takeshita A; Ohno R
Jpn J Cancer Res; 2000 Jun; 91(6):604-11. PubMed ID: 10874212
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]